Acute Coronary Syndrome. Acute ischemic heart disease, unspecified
Conditions
Interventions
Intervention 1: Intervention group: In this group, patients will receive a total of 200mg of CoQ10 supplement (made by Burst Health, USA) in the form of 2 divided doses per day for 12 weeks. Intervent
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 70 Years
Inclusion criteria
Inclusion criteria: Confirmed ACS diagnosis Age less than 70 years Complete satisfaction (patient or patient's companion)
Exclusion criteria
Exclusion criteria: pregnancy breastfeeding GFR<30 ml/min acute kidney injury Taking any type of supplement or lipid-lowering drug except atorvastatin with a daily dose of 80 mg underlying liver disease and high liver enzymes in initial tests Consumption of less than 90% of prescribed supplements Lack of consent to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL Level. Timepoint: 12 weeks after treatment. Method of measurement: laboratory kit.;HDL Level. Timepoint: 12 weeks after treatment. Method of measurement: laboratory kit.;Triglycerides and Cholesterol Level. Timepoint: 12 weeks after treatment. Method of measurement: laboratory kit.;Myalgia Clinical Index Score. Timepoint: 12 weeks after treatment. Method of measurement: laboratory kit.;LDL/HDL Ratio. Timepoint: 12 weeks after treatment. Method of measurement: laboratory kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Hosseinizade
Shahid Beheshti University of Medical Sciences
Outcome results
None listed